

**INFORMATION  
DISCLOSURE  
STATEMENT**

SHEET 1 OF 1

*Complete if known*

Application Number: 09/980,913

Filing Date: May 21, 2002

First Named Inventor: Ernest Arenas, et al.

Group Art Unit: 1636

Examiner Name: Gerald G. Loffers Jr. *LAURA Mc GLEEN*

Attorney Docket Number: 0380-P02709US0

**UNITED STATES PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
<i>LM</i>	A1	6,833,269 B2	12-21-2004	Carpenter

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

**OTHER PRIOR ART - NON-PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

EXAMINER'S  
SIGNATURE

*Laura McGleen*

DATE  
CONSIDERED

*7/13/05*

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



# INFORMATION DISCLOSURE STATEMENT

SHEET 1 OF 2

Complete if known

Application Number: 09/980,913

Filing Date: May 21, 2002

First Named Inventor: Ernest Arenas, et al.

Group Art Unit: 1636

Examiner Name: ~~Gerald G. Leffers Jr.~~ LAURA MCGILLEN

Attorney Docket Number: 0380-P02709US0

## UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1			

## FOREIGN PATENT DOCUMENTS


EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1				

## OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
SPM	C1	Haque NS, LeBlanc CJ, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant. 1997 May-Jun;6(3):239-48.
SPM	C2	Åkerud P., Canals J., Snyder E.Y. and Arenas E. (2001) Neuroprotection through delivery of GDNF by neural stem cells in a mouse model of Parkinson's disease. Journal of Neuroscience, 21: 8108-8118.
SPM	C3	Åkerud P., Holm P.C., Castelo-Branco G., Sousa K., Rodriguez FJ. and Arenas E. (2002) Persephin-overexpressing neural stem cells regulate the function of nigrostriatal dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Molecular and Cellular Neuroscience, 21: 205-222.
SPM	C4	Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol. 2003 Oct;250 Suppl 3:III44-6.
SPM	C5	Dunnett SB, Björklund A, Lindvall O. (2001) Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2001, 2(5):365-9.
SPM	C6	Von Bohlen und Halbach OB, Schober A, Kriegstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77.
SPM	C7	Schwarz J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol. 2003 Dec;16 Suppl 1:S27-33.

EXAMINER'S SIGNATURE	Laura McGillem	DATE CONSIDERED	7/13/05
----------------------	----------------	-----------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

 <p><b>INFORMATION DISCLOSURE STATEMENT</b></p>	<i>Complete if known</i>	
	Application Number: 09/980,913	
	Filing Date: May 21, 2002	
	First Named Inventor: Ernest Arenas, et al.	
	Group Art Unit: 1636	
	Examiner Name: <del>Gerald G. Leffers Jr.</del> <b>LAURA MCGILLEM</b>	
SHEET 2 OF 2		Attorney Docket Number: 0380-P02709US0

<i>LM</i>	C8	Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003 May;9(5):589-95.
<i>LM</i>	C9	Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290(5492): 767-773.
<i>LM</i>	C10	Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003 Jul;2(7):437-45.
<i>LM</i>	C11	Wagner J., Åkerud P., Castro D., Holm P C., Canals J M., Snyder E Y., Perlmann T. and Arenas E. (1999). Induction of a Midbrain Dopaminergic Phenotype in Nurr1-Overexpressing Neural Stem Cells. Nature Biotechnology, 17: 653-659
<i>LM</i>	C12	Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, Defer G, Samson Y, Peschanski M, Hantraye P, Cesaro P, Remy P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord. 2003 Aug;18(8):928-32.
<i>LM</i>	C13	Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):741-52.
<i>LM</i>	C14	Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. Related Articles, Links Abstract Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000 Nov;48(5):689-95.
<i>LM</i>	C15	KIRIK, D., et al., "Localized striatal delivery of GDNF as a treatment for Parkinson disease", Nature Neuroscience, vol. 7: p. 105-110, (2004).

EXAMINER'S SIGNATURE	<i>Laura McGillem</i>	DATE CONSIDERED	7/13/08
----------------------	-----------------------	-----------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.